MX2012000424A - L-asparaginasa pegilada. - Google Patents
L-asparaginasa pegilada.Info
- Publication number
- MX2012000424A MX2012000424A MX2012000424A MX2012000424A MX2012000424A MX 2012000424 A MX2012000424 A MX 2012000424A MX 2012000424 A MX2012000424 A MX 2012000424A MX 2012000424 A MX2012000424 A MX 2012000424A MX 2012000424 A MX2012000424 A MX 2012000424A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugate
- disclosed
- asparaginase
- protein
- polyethylene glycol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un conjugado de una proteína que tiene actividad de L-asparagina aminohidrolasa sustancial y polietilenglicol. En particular, el polietilenglicol tiene un peso molecular menor que o igual a aproximadamente 5000 Da y la proteína es una L-asparaginasa de Erwinia. El conjugado de la invención ha demostrado propiedades superiores tal como mantenimiento de un nivel elevado de actividad in vitro y un incremento inesperado en la vida media in vivo. También se describen métodos para producir el conjugado y el uso del conjugado en terapia. En particular, se describe un método para uso del conjugado en el tratamiento de cáncer, particularmente Leucemia Linfoblástica Aguda (ALL). Más específicamente, se describe un método para el uso del conjugado como una terapia de segunda línea para pacientes quienes han desarrollado hipersensibilidad o han tenido una recaída de la enfermedad después del tratamiento con otras preparaciones con L-asparaginasa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22332009P | 2009-07-06 | 2009-07-06 | |
PCT/EP2010/054156 WO2011003633A1 (en) | 2009-07-06 | 2010-03-30 | Pegylated l-asparaginase |
PCT/EP2010/059599 WO2011003886A1 (en) | 2009-07-06 | 2010-07-06 | Pegylated l-asparaginase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012000424A true MX2012000424A (es) | 2012-07-23 |
Family
ID=42232655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000424A MX2012000424A (es) | 2009-07-06 | 2010-07-06 | L-asparaginasa pegilada. |
Country Status (26)
Country | Link |
---|---|
US (6) | US20120100121A1 (es) |
JP (1) | JP6014956B2 (es) |
KR (1) | KR101731999B1 (es) |
CN (1) | CN102573917B (es) |
AU (1) | AU2010270294B2 (es) |
BR (1) | BR112012000367A2 (es) |
CA (1) | CA2767149C (es) |
CO (1) | CO6612174A2 (es) |
DK (1) | DK2451486T4 (es) |
EA (1) | EA021168B1 (es) |
ES (1) | ES2636476T5 (es) |
FI (1) | FI2451486T4 (es) |
HK (1) | HK1173092A1 (es) |
HU (1) | HUE035771T2 (es) |
IL (1) | IL217392A (es) |
IN (1) | IN2012DN00958A (es) |
LT (1) | LT2451486T (es) |
MA (1) | MA33503B1 (es) |
MX (1) | MX2012000424A (es) |
MY (1) | MY180758A (es) |
NZ (1) | NZ597912A (es) |
PE (2) | PE20161325A1 (es) |
PT (1) | PT2451486T (es) |
SG (1) | SG176984A1 (es) |
UA (1) | UA104634C2 (es) |
WO (2) | WO2011003633A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE531779C2 (sv) * | 2007-11-26 | 2009-08-04 | Promimic Ab | Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer |
WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
WO2015038639A1 (en) * | 2013-09-10 | 2015-03-19 | Sandia Corporation | Therapeutic asparaginases |
CN104046600B (zh) * | 2013-12-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
BR102014000585B1 (pt) | 2014-01-10 | 2021-01-12 | Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação | l-asparaginase recombinante de zymomonas |
US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
CN105802948B (zh) | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
WO2017055484A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining the metabolic status of lymphomas |
CA3054286A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
KR20230162139A (ko) * | 2016-06-01 | 2023-11-28 | 세르비에 아이피 유케이 리미티드 | 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법 |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504418B2 (en) * | 2016-11-04 | 2022-11-22 | Crowpierce Technologies, Llc | Endotoxin free asparaginase |
SG11201912625QA (en) * | 2017-06-21 | 2020-01-30 | Jazz Pharmaceuticals Ireland Ltd | Modified l-asparaginase |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
EP3701036A4 (en) | 2017-10-27 | 2021-09-01 | Pfenex Inc. | METHOD OF MANUFACTURING RECOMBINANT E. COLI |
SG11202002943PA (en) * | 2017-10-27 | 2020-05-28 | Pfenex Inc | Method for production of recombinant erwinia asparaginase |
MX2020005567A (es) * | 2017-11-30 | 2020-08-20 | Jazz Pharmaceuticals Ireland Ltd | Metodos de tratamiento con asparaginasa. |
WO2019204636A1 (en) * | 2018-04-19 | 2019-10-24 | Kindred Biosciences, Inc. | Variant asparaginase polypeptides for medical use |
CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
AU2020371963A1 (en) * | 2019-10-25 | 2022-05-26 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant L-asparaginase |
KR102269634B1 (ko) * | 2019-10-31 | 2021-06-25 | 대상 주식회사 | ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 |
CN116916966A (zh) | 2020-12-23 | 2023-10-20 | 爵士制药爱尔兰有限公司 | 纯化电荷屏蔽融合蛋白的方法 |
WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2024008659A1 (en) | 2022-07-04 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma |
WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
AU2002332371A1 (en) * | 2001-08-22 | 2003-03-10 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha | Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than |
ES2420581T3 (es) | 2003-03-14 | 2013-08-26 | Biogenerix Gmbh | Polímeros solubles en agua ramificados y sus conjugados |
WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
US20090167164A1 (en) | 2006-04-21 | 2009-07-02 | Konica Minolta Holdings, Inc. | Gas barrier film, resin base for organic electroluminescent device, organic electroluminescent device using the same, and method for producing gas barrier film |
WO2008110513A1 (en) * | 2007-03-09 | 2008-09-18 | Novozymes A/S | Thermostable asparaginases |
WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
-
2010
- 2010-03-30 WO PCT/EP2010/054156 patent/WO2011003633A1/en active Application Filing
- 2010-07-06 DK DK10730170.7T patent/DK2451486T4/da active
- 2010-07-06 JP JP2012518956A patent/JP6014956B2/ja active Active
- 2010-07-06 AU AU2010270294A patent/AU2010270294B2/en active Active
- 2010-07-06 FI FIEP10730170.7T patent/FI2451486T4/fi active
- 2010-07-06 EA EA201270134A patent/EA021168B1/ru not_active IP Right Cessation
- 2010-07-06 UA UAA201201135A patent/UA104634C2/ru unknown
- 2010-07-06 SG SG2011096013A patent/SG176984A1/en unknown
- 2010-07-06 PE PE2016001555A patent/PE20161325A1/es unknown
- 2010-07-06 KR KR1020127003202A patent/KR101731999B1/ko active IP Right Grant
- 2010-07-06 PT PT107301707T patent/PT2451486T/pt unknown
- 2010-07-06 MY MYPI2012000054A patent/MY180758A/en unknown
- 2010-07-06 LT LTEP10730170.7T patent/LT2451486T/lt unknown
- 2010-07-06 NZ NZ597912A patent/NZ597912A/en unknown
- 2010-07-06 HU HUE10730170A patent/HUE035771T2/en unknown
- 2010-07-06 US US13/382,276 patent/US20120100121A1/en not_active Abandoned
- 2010-07-06 WO PCT/EP2010/059599 patent/WO2011003886A1/en active Application Filing
- 2010-07-06 MX MX2012000424A patent/MX2012000424A/es active IP Right Grant
- 2010-07-06 CA CA2767149A patent/CA2767149C/en active Active
- 2010-07-06 BR BR112012000367A patent/BR112012000367A2/pt not_active Application Discontinuation
- 2010-07-06 MA MA34598A patent/MA33503B1/fr unknown
- 2010-07-06 CN CN201080030392.6A patent/CN102573917B/zh active Active
- 2010-07-06 PE PE2012000023A patent/PE20120501A1/es not_active Application Discontinuation
- 2010-07-06 ES ES10730170T patent/ES2636476T5/es active Active
-
2012
- 2012-01-05 IL IL217392A patent/IL217392A/en active IP Right Grant
- 2012-02-02 IN IN958DEN2012 patent/IN2012DN00958A/en unknown
- 2012-02-06 CO CO12020409A patent/CO6612174A2/es unknown
-
2013
- 2013-01-11 HK HK13100524.0A patent/HK1173092A1/xx unknown
-
2015
- 2015-08-05 US US14/819,305 patent/US9920311B2/en not_active Ceased
-
2018
- 2018-02-01 US US15/886,216 patent/US20180346900A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,764 patent/USRE49736E1/en active Active
- 2020-05-18 US US16/877,324 patent/US11046946B2/en active Active
-
2021
- 2021-06-03 US US17/338,508 patent/US20210348151A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY180758A (en) | Pegylated l-asparaginase | |
CY1119779T1 (el) | Πεγκυλiωmenh l-ασπαραγιναση | |
US11872287B2 (en) | Compositions and methods of treating muscle atrophy and myotonic dystrophy | |
Liu et al. | Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice | |
MX2011007702A (es) | Composiciones farmaceuticas que comprenden imidazoquinolin(aminas) y derivados de las mismas apropiados para administraccion local. | |
MX368966B (es) | Conjugados de proteina-polimero-farmaco. | |
JO2932B1 (en) | Lyspro insulin compounds linked to PEG | |
SG148997A1 (en) | Powders comprising low molecular dextran and methods of producing those powders | |
US20210301290A1 (en) | Compositions and methods of treating facioscapulohumeral muscular dystrophy | |
EP2061456A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME | |
EP3444351B1 (en) | Ribonucleic acid aptamer having inhibitory effect on non-small cell lung cancer, and pharmaceutical composition comprising same | |
WO2005017130A3 (en) | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof | |
WO2005092878A3 (en) | Schweinfurthin analogues | |
WO2009139855A3 (en) | Pharmaceutical compositions of somatostatin-dopamine conjugates | |
NZ609440A (en) | Preventative or therapeutic agent for fibrosis | |
EP1496979A4 (en) | ADENOVIRAL-PROTAMINE VECTOR COMPLEXES AND METHODS OF USE | |
SI1699468T1 (sl) | Farmacevtski sestavek, ki obsega kompleks cink-hialuronan, za zdravljenje multiple skleroze | |
WO2008087340A3 (fr) | UTILISATION D' OLIGO-β-(1,3)-GLUCANES MODIFIES POUR LE TRAITEMENT DE MALADIES DU SYSTEME IMMUNITAIRE, OLIGO-β-(1,3)-GLUCANE-(1,3)- MANNOSE, OLIGO-β-(1.3)-GLUCANE-(1,3)- MANNITOL ET LEURS DERIVES, LEURS PROCEDES DE PREPARATION ET MEDICAMENTS LES CONTENANT | |
CN105969772A (zh) | 一种靶向抑制PRDX5基因表达的shRNA | |
US11999955B2 (en) | Compositions and methods of treating facioscapulohumeral muscular dystrophy | |
Santhi et al. | Antioxidative role of Terminalia catappa leaf protein against ELA induced mice | |
WO2024077259A3 (en) | Compositions and methods for degradation of lipofuscin cycloretinal by msp1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |